keyword
MENU ▼
Read by QxMD icon Read
search

belimumab

keyword
https://www.readbyqxmd.com/read/29180126/belimumab-in-the-treatment-of-systemic-lupus-erythematous-an-evidence-based-review-of-its-place-in-therapy
#1
REVIEW
Frederico Marcondes, Morton Scheinberg
INTRODUCTION: Systemic lupus erythematous is an autoimmune disease with diverse clinical features and has its development associated with a complexity of genetic, hormonal and environmental factors and the development of autoantibodies. Identification of new treatments is currently an area of intense investigation. Belimumab is the first biologic approved for the treatment of the disease inhibiting the excessive B cell activity observed in these patients and consequently reduction of autoantibodies...
November 24, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29113694/-lupus-erythematosus-treatment-with-belimumab-in-daily-practice-retrospective-study-of-15-patients
#2
E Garval, J-L Pennaforte, R Jaussaud, A Servettaz, P Bernard, Z Reguiai
BACKGROUND: Belimumab (an anti-BLyS monoclonal antibody) was recently approved for the treatment of systemic lupus erythematosus (SLE). The aim of the study was to describe efficacy and safety of the drug as well as its impact on serologic parameters and the role of long-term systemic sparing of treatment in clinical practice in LE. PATIENTS AND METHODS: We conducted a retrospective study at Reims University Hospital between 2012 and 2016 including consecutive patients with LE treated with belimumab...
November 4, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29101479/b-cell-based-treatments-in-sle-past-experience-and-current-directions
#3
REVIEW
Stamatis-Nick C Liossis, Chrysanthi Staveri
PURPOSE OF REVIEW: B cells have been targeted recently by novel therapeutic approaches in patients with SLE. In this review, we discuss recent data that have emerged on this issue placing special emphasis in studies published during the last 5 years. RECENT FINDINGS: Despite the negative results stemming from double-blind placebo-controlled studies, B cell depletion with rituximab is indeed employed worldwide, particularly in standard treatment refractory lupus, with promising results...
November 4, 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/29073351/belimumab-for-the-treatment-of-early-diffuse-systemic-sclerosis-results-of-a-randomized-double-blind-placebo-controlled-pilot-trial
#4
Jessica K Gordon, Viktor Martyanov, Jennifer M Franks, Elana J Bernstein, Jackie Szymonifka, Cynthia Magro, Horatio F Wildman, Tammara A Wood, Michael L Whitfield, Robert F Spiera
OBJECTIVE: To assess the safety and efficacy of treatment with belimumab in patients with early diffuse cutaneous systemic sclerosis (dcSSc) treated with background mycophenolate mofetil (MMF). METHODS: In this 52-week, investigator-initiated, single-center, double-blind, placebo-controlled, pilot study, 20 patients recently started on MMF were randomized 1:1 to additionally receive belimumab 10 mg/kg intravenously or placebo. We assessed safety, efficacy and differential gene expression (NCT01670565)...
October 26, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29029693/what-can-google-and-wikipedia-can-tell-us-about-a-disease-big-data-trends-analysis-in-systemic-lupus-erythematosus
#5
Savino Sciascia, Massimo Radin
OBJECTIVE: To investigate trends of Internet search volumes linked to Systemic Lupus Erythematosus (SLE), on-going clinical trials and research developments associated to the disease, using Big Data monitoring and data mining. METHODS: We performed a longitudinal analysis based on the large amount of data generated by Google Trends, scientific search tools (SCOPUS, Medline/Pubmed/ClinicalTrails.gov) considering 'SLE', and 'lupus' in a 5-year web-based research. Wikipedia page views were also analysed using WikiTrends and the results were compared with the search volumes generated by Google Trends...
November 2017: International Journal of Medical Informatics
https://www.readbyqxmd.com/read/28992184/immune-complexes-containing-serum-b-cell-activating-factor-and-immunoglobulin-g-correlate-with-disease-activity-in-systemic-lupus-erythematosus
#6
Justa Friebus-Kardash, Leonore Branco, Camillo Ribi, Carlo Chizzolini, Uyen Huynh-Do, Denise Dubler, Pascale Roux-Lombard, Sebastian Dolff, Andreas Kribben, Ute Eisenberger, Marten Trendelenburg
Background: B-cell activating factor belonging to the TNF family (BAFF) is important for the survival of autoreactive B-cells in systemic lupus erythematosus (SLE). However, the association between serum BAFF levels and SLE disease activity is controversial. Independently, autoantibodies targeting BAFF [immunoglobulin G (IgG) anti-BAFF] have also been described in SLE patients and were associated with increased disease activity. The aim of our study was to analyse the relationship between SLE disease manifestations and serum levels of BAFF, IgG anti-BAFF and BAFF-IgG complexes...
August 8, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28963832/-membranous-glomerulonephritis-mgn-ongoing-studies
#7
REVIEW
Gaetano La Manna, Olga Baraldi, Vania Cunia, Valeria Corradetti, Valeria Aiello, Marco Busutti, Lorenzo Gasperoni, Alessandra Spazzoli, Giorgia Comai
The membranous nephropathy (MN) is the major cause of nephrotic syndrome in in the adult, account for 20% of cases with annual incidence is 1 in 100.000. In the past 10 years, the role of podocytes has been identified; environmental triggers in genetically predisposed patients can activate podocytes to exhibit antigenic epitopes (receptor of phospholipase A2, thrombospondin type 1) that become targets of specific autoantibodies with subsequent complement activation. The discovery of this mechanisms has opened new horizons in the therapy of MN and novel drugs are available with more specific mechanism of action...
September 28, 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/28956281/patient-evaluation-of-satisfaction-and-outcomes-with-an-autoinjector-for-self-administration-of-subcutaneous-belimumab-in-patients-with-systemic-lupus-erythematosus
#8
Ebony Dashiell-Aje, Gale Harding, Katie Pascoe, Jane DeVries, Pamela Berry, Sulabha Ramachandran
OBJECTIVE: This study assessed patient experiences of using an autoinjector device to self-administer subcutaneous belimumab for the treatment of systemic lupus erythematosus (SLE). Satisfaction, ease and convenience of use, and confidence with the device were assessed, in addition to overall experience with belimumab. METHODS: This cross-sectional study was conducted among patients who completed a phase IIb open-label, multi-dose usability, tolerability, and safety study of subcutaneous belimumab (NCT02124798), in which patients receiving intravenous belimumab or subcutaneous belimumab using a prefilled syringe were switched to eight weekly self-administered doses of subcutaneous belimumab using the autoinjector...
September 27, 2017: Patient
https://www.readbyqxmd.com/read/28935492/clinical-predictors-of-response-and-discontinuation-of-belimumab-in-patients-with-systemic-lupus-erythematosus-in-real-life-setting-results-of-a-large-multicentric-nationwide-study
#9
Luca Iaccarino, Laura Andreoli, Elena Bartoloni Bocci, Alessandra Bortoluzzi, Fulvia Ceccarelli, Fabrizio Conti, Rossella De Angelis, Ginevra De Marchi, Salvatore De Vita, Andrea Di Matteo, Giacomo Emmi, Lorenzo Emmi, Mariele Gatto, Roberto Gerli, Maria Gerosa, Marcello Govoni, Maddalena Larosa, Pier Luigi Meroni, Marta Mosca, Giulia Pazzola, Rossella Reggia, Francesca Saccon, Carlo Salvarani, Chiara Tani, Margherita Zen, Anna Chiara Frigo, Angela Tincani, Andrea Doria
OBJECTIVE: To investigate efficacy, safety and survival of belimumab and to identify predictors of drug response and drug discontinuation in patients with active SLE in clinical practice. PATIENTS AND METHODS: Data of SLE patients, treated with belimumab, from 11 Italian prospective cohorts were analyzed. SLEDAI-2K, anti-dsDNA, C3, C4, prednisone daily dose, DAS-28, 24-h proteinuria, CLASIa (Cutaneous LE Disease Area and Severity Index Activity) were recorded at baseline and every 6 months...
September 18, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28887801/population-pharmacokinetic-and-pharmacodynamic-analysis-of-belimumab-administered-subcutaneously-in-healthy-volunteers-and-patients-with-systemic-lupus-erythematosus
#10
Herbert Struemper, Mita Thapar, David Roth
BACKGROUND: Intravenous belimumab 10 mg/kg every 4 weeks is indicated in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard systemic lupus erythematosus care. Subcutaneous 200-mg weekly administration, which may prove more convenient for patients and improve adherence, is currently under investigation. OBJECTIVE: The objective of this study was to characterize the population pharmacokinetics and exposure-efficacy response of subcutaneous belimumab in a pooled analysis of pharmacokinetic data [phase I: BEL114448 (NCT01583530) and BEL116119 (NCT01516450) in healthy subjects (n = 134); phase III: BEL112341 (NCT01484496) in adults with systemic lupus erythematosus (n = 554)] and pharmacodynamic data [BEL112341 in adults with systemic lupus erythematosus (n = 833)]...
September 8, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28877634/certolizumab-an-anti-tnf-safe-during-pregancy-the-crib-study-results-an-interview-with-professor-xavier-mariette
#11
Xavier Mariette
Professor Xavier Mariette, MD, PhD, has served as the Head of the Rheumatology Department of Bicêtre Hospital, Paris-Sud University since 1999, a role he took following 10 years of practice of clinical immunology. Professor Mariette has initiated a number of clinical research studies on biotherapies in autoimmune diseases. He is the head of the French RATIO (Research Axed on Tolerance of Biotherapy) observatory, collecting specific rare serious adverse events in patients treated with anti-TNF. He initiated the French AIR (Autoimmunity and Rituximab) and ORA (Orencia and Rheumatoid arthritis) registries of patients with autoimmune diseases treated with rituximab and abatacept...
September 2017: Immunotherapy
https://www.readbyqxmd.com/read/28862513/relationship-between-glucocorticoid-dose-and-adverse-events-in-systemic-lupus-erythematosus-data-from-a-randomized-clinical-trial
#12
S Emamikia, C Gentline, K Chatzidionysiou, L Arnaud, R van Vollenhoven
OBJECTIVE: The aim was to obtain a better understanding of the relationship between exposure to glucocorticoids (GCs) and adverse events (AEs) reported in a randomized controlled trial (RCT) in systemic lupus erythematosus (SLE) patients. METHOD: We used data from the BLISS-76 trial on belimumab. The data were accessed through an agreement under the SHARE mechanism. AEs were grouped according to medical relevance, i.e. based on similarity of symptoms and pathophysiology...
September 1, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28853005/unmet-needs-in-the-pathogenesis-and-treatment-of-systemic-lupus-erythematosus
#13
REVIEW
Jyoti Bakshi, Beatriz Tejera Segura, Christopher Wincup, Anisur Rahman
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a prevalence of approximately 1 in 1000. Over the last 30 years, advances in treatment such as use of corticosteroids and immunosuppressants have improved life expectancy and quality of life for patients with lupus and the key unmet needs have therefore changed. With the reduced mortality from disease activity, development of cardiovascular disease (CVD) has become an increasingly important cause of death in patients with SLE. The increased CVD risk in these patients is partly, but not fully explained by standard risk factors, and abnormalities in the immune response to lipids may play a role...
August 29, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28803702/patient-and-physician-reported-satisfaction-with-systemic-lupus-erythematosus-treatment-in-us-clinical-practice
#14
Katie Pascoe, Steve Lobosco, David Bell, Ben Hoskin, David J Chang, Bonnie Pobiner, Sulabha Ramachandran
PURPOSE: This two-part study comprised two descriptive, cross-sectional surveys to evaluate treatment satisfaction among patients with systemic lupus erythematosus (SLE) and their physicians from US clinical practices. The Lupus Plus Project (LPP; part one) involved belimumab-containing regimens; the Disease Specific Program (DSP; part two) included all treatments and was designed to build on the body of evidence from part one. METHODS: The LPP recruited patients receiving belimumab, and comprised 2 paper questionnaires: a patient self-completion questionnaire (PSC) and a patient record form (PRF) completed by the physician...
August 10, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28800401/lupus-nephritis-and-b-cell-targeting-therapy
#15
Matthias Cassia, Federico Alberici, Maurizio Gallieni, David Jayne
Lupus Nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE) with a significant prognostic impact. Over a prolonged course, an exhaustion of treatment alternatives may occur and further therapeutic options are needed. B cells play a pivotal role in disease pathogenesis and represent an attractive therapeutic target. Areas covered: This review provides an update regarding targeting B cells in LN. The rational for this approach, as well as currently available and future targets are discussed...
October 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28798699/schizophrenia-or-atypical-lupus-erythematosus-with-predominant-psychiatric-manifestations-over-25%C3%A2-years-case-analysis-and-review
#16
Axel Mack, Christiane Pfeiffer, E Marion Schneider, Karl Bechter
We observed a case over 25 years of relapsing-remitting schizophrenic spectrum disorder, varying regarding the main symptomatology between more depressive or more schizoaffective or rather typical schizophrenic syndrome. Diseased phases were repeatedly accompanied by minor skin lesions, which were initially classified as mixed tissue disorder. Psychotic phases were waxing-waning over years. During one later relapse, skin involvement was severe, classified to likely represent an allergic reaction to psychopharmaca; this generalized exanthema remitted rapidly with cortisone treatment and azathioprine...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/28770706/efficacy-of-belimumab-for-the-long-term-maintenance-therapy-of-thrombocytopenia-in-systemic-lupus-erythematosus
#17
Ginevra De Marchi, Luca Quartuccio, Milena Bond, Salvatore De Vita
No abstract text is available yet for this article.
July 26, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28770613/novel-biomarkers-for-systemic-lupus-erythematosus
#18
Jinrong Zeng, Haijing Wu, Ming Zhao, Qianjin Lu
Systemic lupus erythematosus (SLE) is a complex and highly heterogeneous disease. By now, no novel drug has been approved by the US FDA in the past 50 years, except Belimumab, a monoclonal antibody to inhibit B-cell activating factor. The stagnating drug development of lupus may be due to our limited understanding of disease etiopathogenesis and the extreme heterogeneity of patient population. Thus, the individualized treatment for SLE becomes necessary. Recently, biomarkers have shown potential in individualized treatment...
August 3, 2017: Biomarkers in Medicine
https://www.readbyqxmd.com/read/28745239/therapeutic-interventions-of-tissue-specific-autoimmune-onset-in-systemic-lupus-erythematosus
#19
Subhajit Dasgupta
Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease. The onset of SLE has been found to affect kidney, bone, cardiovascular and central nervous system. Auto activation of B cells and T helper cells together are known to develop self-reactive immune responses in SLE. The therapy still includes corticosteroids to prevent allergic manifestations and inflammatory immune responses. Recent observations suggested that, mycophenolate mofetil and cyclophosphamide treatment in combination with corticosteroids have benefit to control disease manifestations...
July 25, 2017: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/28711556/medicine-based-evidence-for-individualized-decision-making-case-study-of-systemic-lupus-erythematosus
#20
RANDOMIZED CONTROLLED TRIAL
Ashley E Wivel, Kate Lapane, Christi Kleoudis, Burton H Singer, Ralph I Horwitz
BACKGROUND: To guide management decisions for an index patient, evidence is required from comparisons between approximate matches to the profile of the index case, where some matches contain responses to treatment and others act as controls. METHODS: We describe a method for constructing clinically relevant histories/profiles using data collected but unreported from 2 recent phase 3 randomized controlled trials assessing belimumab in subjects with clinically active and serologically positive systemic lupus erythematosus...
November 2017: American Journal of Medicine
keyword
keyword
57741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"